
FDA grants accelerated approval to dostarlimab for MSI-H or dMMR rectal cancer
The approval
The US Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli), from GSK, on October 19, 2026. It is approved for adults with stage II or III locally advanced rectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). The FDA acted about four months before its goal date, which had been set for February 2027. The application had priority review, and the drug holds Breakthrough Therapy designation for this use.
The evidence
- The decision rests on interim results from AZUR-1, a single-arm phase 2 study of dostarlimab alone in 154 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer.
- The FDA also reviewed a separate 50-patient investigator-led trial, which reported a clinical complete response rate at 12 months of 93% (95% confidence interval 82% to 99%).
A single-arm study has no comparison group, so the results show response but not how the drug compares directly with standard treatment.
Dosing
The recommended dose is 500 mg every three weeks, until disease progression or unacceptable toxicity, for up to nine cycles.
Why it is accelerated approval
Accelerated approval allows a drug to reach patients earlier based on a measure that is reasonably likely to predict benefit. The FDA said longer follow-up is needed to establish how long responses last and how often the cancer returns. GSK must continue to follow patients to confirm that the responses translate into lasting clinical benefit.
What it could change
Standard care for locally advanced rectal cancer often involves chemotherapy, radiation and surgery, which can have long-term effects. A treatment that leads to complete responses in this genetic subgroup could allow some patients to avoid some of those steps. Only a minority of rectal cancers are dMMR or MSI-H, so testing matters. Patients should discuss testing and options with their cancer team.
What to watch
- Full AZUR-1 data, which one report said GSK planned to present at the ESMO Congress in October 2026.
- Long-term follow-up on response duration and recurrence.
- Updates to treatment guidelines and insurance coverage.
This article is general information and not medical advice. For another regulatory milestone, see our report on uniQure's Huntington's disease gene therapy application.
Advertisement
